评估胸水（PF）N末端B型利钠肽原（NTproBNP）水平在识别心衰竭（HF）相关胸腔积液（PE）中的鉴别特性。
适应症：Pleural Effusion、Heart Failure、Malignant Neoplasm、Fluid Overload、Hypoalbuminemia、Renal Failure、Cirrhosis、Infections
入组条件
纳入标准
- Patients hospitalized for heart failure and pleural effusion
- Pleural tapping indicated for pleural fluid analysis.
- Aged 18 years old or above
排除标准
- History of intrapleural therapy (including talc and fibrinolytic) in the ipsilateral pleural space.
- History of surgical decortication or pleurodesis in the ipsilateral pleural space.
- Ipsilateral thoracic or cardiac surgery in the past 3 months.
- Failure to obtain informed consent due to the patient's refusal or cognitive impairment.
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。